Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia

被引:0
|
作者
Claudia Stefanutti
机构
[1] “Sapienza” University of Rome,Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Regional Centre (Lazio) for Rare Diseases, Immunohematology and Transfusion Medicine, Department of Molecular Medicine
[2] “Umberto I” Hospital,undefined
来源
关键词
Homozygous familial hypercholesterolemia; Lomitapide; Cardiovascular disease; Lipoprotein apheresis; Drug therapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 50 条
  • [1] Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
    Stefanutti, Claudia
    CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (08)
  • [2] Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolemia phenotype
    Fountas, E.
    Diakoumakou, O.
    Kolovou, V.
    Stratakis, S.
    Zacharis, E.
    Liberopoulos, E.
    Matsouka, F.
    Tsoutsinos, A.
    Mastorakou, I.
    Katsikas, T.
    Mavrogeni, S.
    Hatzigeorgiou, G.
    Kolovou, G.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3258 - 3258
  • [3] A phase 3 study of the microsomal triglyceride transfer protein (MTP) inhibitor lomitapide in patients with homozygous familial hypercholesterolemia
    Cuchel, M.
    EUROPEAN HEART JOURNAL, 2012, 33 : 951 - 951
  • [5] Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
    Blom, Dirk J.
    Averna, Maurizio R.
    Meagher, Emma A.
    Theron, Hendrik du Toit
    Sirtori, Cesare R.
    Hegele, Robert A.
    Shah, Prediman K.
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni B.
    Larrey, Dominique
    Bloedon, LeAnne T.
    Foulds, Pamela
    Rader, Daniel J.
    Cuchel, Marina
    CIRCULATION, 2017, 136 (03) : 332 - 335
  • [6] Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia
    Kolovou, Genovefa
    Diakoumakou, Olga
    Kolovou, Vana
    Fountas, Epameinondas
    Stratakis, Stavros
    Zacharis, Evangelos
    Liberopoulos, Evangelos N.
    Matsouka, Fedra
    Tsoutsinos, Alexandros
    Mastorakou, Irene
    Katsikas, Theodoros
    Mavrogeni, Sophie
    Hatzigeorgiou, Georgios
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (02) : 157 - 165
  • [7] Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia
    Cuchel, Marina
    Meagher, Emma A.
    Theron, H. du Toit
    Blom, Dirk
    Marais, A. D.
    Hegele, Robert A.
    Averna, Maurizio
    Sirtori, Cesare
    Shah, Prediman K.
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni B.
    du Plessis, A. M. E.
    Bloedon, LeAnne T.
    Rader, Daniel J.
    CIRCULATION, 2012, 126 (21)
  • [8] Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia
    Khoury, Etienne
    Brisson, Diane
    Roy, Nathalie
    Tremblay, Gerald
    Gaudet, Daniel
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (05) : 403 - 414
  • [9] A Phase III Study of Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide (AEGR-733) in Patients With Homozygous Familial Hypercholesterolemia: Interim Results at 6 Months
    Cuchel, Marina
    Meagher, Emma
    Marais, A. D.
    Blom, Dirk J.
    Theron, Hendrik D.
    Baer, Amanda L.
    Bloedon, LeAnne T.
    Sasiela, William J.
    Rader, Daniel J.
    CIRCULATION, 2009, 120 (18) : S441 - S441
  • [10] Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia
    Walsh, Meghan T.
    Hussain, M. Mahmood
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2017, 54 (01) : 26 - 48